NCT01502085 2026-04-03
RZD
Hackensack Meridian Health
Phase 1/2 Completed
Clinical Trials
7 trialsNCT00875056 2026-01-30
MK-0683-103
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03259503 2025-11-10
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03263936 2025-10-16
Epigenetic Reprogramming in Relapse/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT03426891 2025-10-06
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02836548 2025-07-10
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT00838929 2025-05-04
Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases
Thomas Jefferson University
Phase 1 Completed